IMMUNOBIOGRAM® is an endpoint bioassay. It is done with a 10 ml peripheral blood sample per patient. The readout of the bioassay translates in numbers the inhibition of the patient´s T cells proliferative response after exposure to each immunosuppressive drug.
This bioassay is done with a sample of 3D cell culture of PBMCs, some are physiologically stimulated (control +) and the other are not stimulated and serve as control (control -).
A hydrogel containing the PBMCs is loaded in longitudinal channels and immunosuppressive drugs (IS) delivery devices are placed at the edge of the different channels. In each channel an IS concentration gradient takes place due to a passive diffusion process.
After 18-20h of exposure to IS, an indicator of cell proliferation/viability reveals the capacity of IMSs gradient to inhibit the activation of T cells. A quantifiable signal is obtained and properly measured with fluorimetry.
A mathematical model and a software for the data interpretation has been developed to
evaluate the IMBG dose/response curves to IS, and toperform a cluster analysis of patients based on this cellular response.
Overall, this software can qualify the patient´s sensitivity /resistance profile to each IS tested.